Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 11, 2007
JNCI Journal of the National Cancer Institute 2007 99(18):1362-1364; doi:10.1093/jnci/djm164
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/18/1362    most recent
djm164v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Gene Mutation Revelation Points to New Target for Myeloma Treatment, Studies Say

Ken Garber

The first 10% of the full text of this article appears below.

Multiple myeloma is a disease in the spotlight. Although it is relatively rare, accounting for about 2% of all cancers in the U.S., new treatments arrive almost every year. Bortezomib, thalidomide, and lenalidomide have all been approved since 2003, and new bone marrow transplant regimens have extended survival. The multiple myeloma field "has exploded," said Louis Staudt, M.D., Ph.D., of the National Cancer Institute. But the disease is still considered incurable.

Now two papers in the August issue of Cancer Cell mark another advance in myeloma biology, as well as a promising new approach to treatment. Groups led by Staudt and Leif Bergsagel, M.D., of the Mayo Clinic in Scottsdale, Ariz., independently identified a variety of gene mutations and other genetic abnormalities in the NF-{kappa}B signaling pathway in myeloma. The Staudt group concluded that 82% of patients with myeloma have . . . [Full Text of this Article]

Two Paths, One Conclusion

Clinical Implications

A Model Disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?